Notably, PD-L1 expressed on tumor cells directly enhances tumor glycolysis by activating the PI3K/AKT/mTOR pathway, creating a metabolic advantage for tumor survival and further suppressing T cell activity 198. Here, CD274 is linked to neoplasm.